Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma

Table 1

CI and dose reduction values for inhibition on BEL-7402, SMMC-7721, and Huh-7 by combining DOX with ABT-199.

% inhibition	CI	DOX			ABT-199
		Conc. (μmol/L)		Dose reduction	Conc. (μmol/L)		Dose reduction
		Alone	Mix		Alone	Mix
BEL-7402
50	0.6218	0.237	0.098	2.418	12.434	5.888	2.112
75	0.8341	0.532	0.132	4.030	21.875	10.962	1.996
95	1.0126	0.997	0.369	2.701	34.511	27.435	1.258
SMMC-7721
50	0.5832	0.384	0.127	3.024	13.822	5.917	2.336
75	0.7421	0.711	0.218	3.261	24.329	9.998	2.433
95	0.9735	1.203	0.435	2.766	37.096	23.842	1.558
Huh-7
50	0.7125	0.256	0.067	3.821	13.911	7.896	1.762
75	0.8641	0.497	0.158	3.146	28.502	13.866	2.056
95	0.9658	0.899	0.309	2.909	39.710	30.117	1.319